AAHI pioneers immune-enhancing platforms to provide potent, durable, broadly effective, and efficient vaccines and immunotherapies that are accessible to those who most need them.
AAHI in the News
Filter by year
A new study published recently in NPJ Vaccines describes the development of a new thermostable SARS-CoV-2 RNA vaccine by AAHI that induces potent, cross-variant humoral and cellular immune responses in preclinical rodent models. The study demonstrates that the vaccine candidate can be freeze-dried to provide stability at room temperature for six months and refrigerated temperatures for at least 10 months. The approach combines self-amplifying RNA (saRNA) with a unique stable nanostructured lipid carrier (NLC) delivery vehicle containing the adjuvant molecule squalene for optimal vaccine potency. The frozen-liquid SARS-CoV-2 RNA vaccine candidate, AAHI-SC2, is now being evaluated in Phase 1 clinical trials sponsored by ImmunityBio in South Africa, for which the vaccine candidate was well-tolerated (NCT05370040).Read More